Precertification Required for Select Brands

Precertification is required for ferric carboxymaltose (Injectafer), ferric derisomaltose (Monoferric), and ferumoxytol injection (Feraheme). To precertify, call (866) 752-7021 or fax (888) 267-3277. Use the Statement of Medical Necessity (SMN) precertification forms available on the Specialty Pharmacy Precertification webpage.

• Applies to all Aetna participating providers and members in applicable plan designs
• Required for Injectafer, Monoferric, and Feraheme

Prior Authorization for IV Iron Products

Prior authorization is required for IV iron products billed with covered HCPCS/CPT codes when selection criteria in this policy are not clearly met. Provide clinical documentation to demonstrate medical necessity and adherence to policy criteria.

• Prior authorization applies when billing the listed J-codes/HCPCS for IV iron
• Documentation should include rationale for IV use versus oral therapy when applicable

Prior Authorization Triggered by J-code Billing

Coverage for specific IV iron J-codes is conditioned on meeting the policy's selection criteria for those codes (see CPT/HCPCS and criteria sections). Ensure the diagnosis and clinical thresholds align with the indicated J-code being billed.

• Injectafer (J1439) billed per mg — verify indication and selection criteria
• Other J-codes must be supported by corresponding clinical criteria in policy

HCPCS Coding for Triferic Products

Triferic products have distinct HCPCS coding: J1443 describes Triferic solution and J1444 describes Triferic powder packet (0.1 mg iron). Billers must use the correct J-code for the formulation administered; note marketplace availability changes may affect coverage.

• J1443 — Injection, ferric pyrophosphate citrate solution (Triferic)
• J1444 — Injection, ferric pyrophosphate citrate powder, 0.1 mg of iron (Triferic powder packet)
• Triferic/Triferic Avnu were removed from U.S. market in 2022 for business reasons — verify current availability

Clinical Scenarios That Trigger Prior Authorization

Prior authorization is typically triggered when IV iron is preferred or required, including: intolerance or inadequate response to oral iron, severe anemia, anticipated imminent surgery (elective surgery within ~6 weeks), malabsorption states (eg post-bariatric surgery), or when rapid repletion is clinically necessary.

• Oral intolerance, malabsorption, or contraindication to oral iron
• Severe anemia (eg Hb <10 g/dL) or need for rapid iron repletion before surgery
• Non-response to oral iron or inability to adhere to oral therapy

Authorization Considerations: TSAT and Ferritin Thresholds

Authorization decisions incorporate ferritin and TSAT thresholds as operational guides: in CKD and dialysis contexts, IV therapy is commonly considered when TSAT ≤30% and ferritin ≤500 ng/mL; pediatric thresholds may differ and are noted in CKD guidance. For RLS and other conditions, policy references specific ferritin/TSAT cutoffs (eg ferritin ≤75–100 ng/mL and TSAT <20% where applicable).

• CKD operational thresholds: TSAT ≤30% and ferritin ≤500 ng/mL for repeat IV courses
• RLS guidance: consider IV iron when ferritin ≤100 ng/mL or ferritin ≤75 ng/mL for oral trial
• TSAT <20% often used to indicate insufficient iron availability in inflammatory states

Note: Guideline/Trial Discussion Without Explicit Authorization Rules

Some sections of the source contain guideline or trial discussion without explicit authorization rules; when explicit prior authorization criteria are absent, follow the main policy criteria and general documentation requirements.

• Clinical trial and background text may not establish billing triggers
• Rely on policy's stated selection criteria and coding sections for authorization decisions

Requirement: Documented Anemia or Iron Deficiency

Prior authorization requires documented evidence of anemia and/or iron deficiency and a clear clinical rationale for IV iron (eg intolerance to oral iron, malabsorption, ongoing blood loss, or need for rapid repletion). Absent documentation that demonstrates medical necessity, requests risk denial.

• Require baseline hemoglobin, ferritin, TSAT and clinical explanation for IV therapy
• Document prior oral iron trial and reasons for failure or intolerance unless exception applies

Authorization Linked to Product-Specific FDA Indications

Authorization is aligned with FDA-labeled indications for specific products (eg Feraheme, Injectafer, Monoferric) — approve when the member meets the product-specific FDA indication and policy criteria, and when a lower-cost clinically equivalent alternative is contraindicated, intolerant, or ineffective.

• Feraheme: FDA-labeled for iron deficiency anemia in adult patients with CKD or intolerance/unsatisfactory response to oral iron
• Injectafer and Monoferric: approve for FDA-indicated NDD-CKD or intolerance/unsatisfactory response to oral iron
• Brand selection rules: Feraheme/Injectafer reserved when contraindication/intolerance/inefficacy to preferred products demonstrated

Experimental / Investigational and Contraindicated Uses

Aetna considers intravenous iron contraindicated or experimental/investigational for select conditions (denial-risk). Notably, intravenous iron is contraindicated in genetic hemochromatosis or hemochromatosis secondary to iron overload, and is considered experimental for a range of other indications where clinical value is unproven.

• Experimental/Investigational exclusions include: genetic hemochromatosis, anemia of inflammation (excluding IBD), many prophylactic or non-established surgical indications, acute mountain sickness, and certain postpartum/postoperative uses not meeting criteria
• Intrinsic Hepcidin IDx Test considered experimental for management of iron-restricted/overload disorders

ICD-10 Denial Triggers

ICD-10 diagnosis codes that are denial triggers for the listed indications include D62 (acute posthemorrhagic anemia) and D63.8 (anemia in other chronic diseases classified elsewhere). If these codes are submitted for indications that the policy does not cover, authorization may be denied.

• ICD-10 codes listed as not covered for CPB indications: D62, D63.8
• Confirm that submitted ICD-10 codes match covered indications in the policy

Monitoring and Preparedness for Hypersensitivity

Serious hypersensitivity and anaphylactic-type reactions can occur with parenteral iron products. Providers must monitor patients during and after infusion until clinically stable and have personnel and therapies immediately available to manage hypersensitivity reactions.

• Monitor during and after infusion for signs of hypersensitivity, shock, hypotension, loss of consciousness
• Ensure immediate availability of emergency treatment and trained personnel

Perioperative Anemia Assessment and Management

For perioperative anemia, assess and treat iron deficiency prior to elective major surgery when possible. Consider delaying non-urgent surgery to allow diagnosis and treatment; use serum ferritin and TSAT to guide management and choose oral versus IV iron based on severity and timing.

• Screen surgical patients for anemia early; target Hb ≥130 g/L preoperatively when feasible for major surgery
• Prefer oral iron when mild deficiency and time allows; use IV iron for severe deficiency, oral intolerance, or surgery within ~6 weeks

Clinical Thresholds Referenced (Ferritin and TSAT)

Clinical thresholds referenced throughout the policy include ferritin cutoffs and TSAT values to help define absolute versus functional iron deficiency. Ferritin <30 ng/mL is commonly diagnostic of iron deficiency; higher ferritin thresholds (eg <100 ng/mL) are used in inflammatory states; TSAT <20% often indicates insufficient iron availability.

• Ferritin <30 ng/mL — diagnostic of iron deficiency in many settings
• In inflammation/CKD: ferritin <100 ng/mL (or <300 with TSAT considerations) and TSAT <20% used to indicate deficiency
• TSAT <20% commonly used as operational threshold

No Explicit Authorization or Billing Requirement Specified in Some Sections

Certain portions of the source text contain evidence summaries or references without explicit authorization or billing requirements. When no explicit policy billing rule is specified, follow the main policy criteria and coding tables for authorization and claim adjudication.

• Do not infer coverage from background evidence summaries alone
• Refer to the policy's CPT/HCPCS and criteria sections for actionable billing and authorization rules

Potential Denial Risk Where Evidence Is Inconclusive

Where evidence shows no clear benefit (for example, some post-operative settings), requests for IV iron may be at higher risk of denial unless the member meets the policy's documented medical necessity criteria and supporting clinical documentation is provided.

• Potential denial risk: pre-operative/post-operative uses with inconclusive evidence for transfusion reduction
• Ensure robust documentation of indication, labs, and rationale to mitigate denial risk

Pre-Treatment Iron Testing Required

Do not prescribe IV iron empirically. Pre-treatment iron studies (at minimum serum ferritin and TSAT) are required to assess iron status before IV iron administration. Additional tests (eg CRP, soluble transferrin receptor) may be appropriate when inflammation is present.

• Obtain baseline ferritin and TSAT prior to IV iron prescribing
• Consider CRP and soluble transferrin receptor in inflammatory conditions to interpret ferritin

Risk of Denial Without Iron Studies or Clinical Justification

Requests lacking iron studies (ferritin and TSAT) or adequate clinical justification may be denied. Empiric prescribing without laboratory confirmation of iron deficiency or clear rationale is a common denial trigger.

• Risk of denial if no baseline ferritin and TSAT documented
• Provide prior oral iron trial details or documented exception when applicable

Administrative Notes / Non-Clinical Content

Some chunks in the source contain no actionable policy items (administrative or reference-only content). For administrative actions, refer to the Policy History and Additional Information sections and the specialty precertification contact information provided.

• See Policy History for effective date and next review
• See Additional Information for contact links and policy notes

Required Clinical Laboratory Documentation for Initial Approval

Required clinical laboratory documentation for initial approval generally includes baseline hemoglobin (Hb), serum ferritin, and transferrin saturation (TSAT). Where relevant, include CRP, soluble transferrin receptor, reticulocyte hemoglobin content, and other tests to clarify iron status in inflammatory or complex cases.

• Baseline labs: Hb, ferritin, TSAT (required)
• Additional recommended tests: CRP, sTfR, CHr, serum iron, TIBC as clinically indicated

Recommended Clinical Monitoring Parameters

Recommended clinical monitoring parameters include baseline and follow-up hemoglobin, ferritin, TSAT, and monitoring for infusion-related adverse events. Monitor patients during and after infusion for hypersensitivity and report adverse events per standard practice.

• Baseline and periodic Hb, ferritin, TSAT assessments to evaluate response
• Observe for infusion reactions during and after administration; document any hypersensitivity

Required Baseline Labs and Timing

Document baseline labs and timing when evaluating pre-operative anemia or other indications: obtain tests close enough to the planned therapy to reflect current iron status. For repeat IV courses in CKD, document TSAT and ferritin values used to justify re-dosing (eg TSAT ≤30% and ferritin ≤500 ng/mL).

• Baseline Hb, ferritin, TSAT should be recent and included with prior authorization requests
• For CKD/dialysis patients, document TSAT ≤30% and ferritin ≤500 ng/mL when applicable

Policy History and Administrative Information

Policy history and additional administrative information (effective date, last review, next review) are maintained in the Policy History and Additional Information sections. The policy effective date is 11/13/2001 with last review 02/01/2024 and next review 12/12/2024. Providers should consult those sections for updates and administrative contacts.

• Effective: 11/13/2001; Last Review: 02/01/2024; Next Review: 12/12/2024
• Refer to Additional Information for policy notes and Aetna contact links

Step Therapy: Oral Iron Trial Expectations and Exceptions

Step therapy preference: when feasible, oral iron should be tried before IV iron for mild deficiency, non-dialysis CKD, and elective perioperative optimization. Exceptions include severe anemia, intolerance or malabsorption, ongoing blood loss, or need for rapid repletion.

• Oral-first approach expected in non-dialysis CKD when appropriate (trial 1–3 months) and in mild iron deficiency
• Exceptions: severe anemia (eg Hb <10 g/dL), intolerance to oral iron, malabsorption, or imminent surgery

When No Step Therapy Is Specified

No mandatory step therapy requirements are specified in some policy sections; where the policy does not mandate a specific step, clinicians should provide supporting evidence and rationale for chosen therapy. Comparative evidence exists but does not always impose required step rules.

• If no step requirement is specified, document clinical justification for IV use
• Evidence comparisons in background do not equal mandatory step-therapy rules

Provider Summary: Actions to Support Authorization and Avoid Denials

In summary, prior authorization and documentation for IV iron require: correct HCPCS/J-code billing, baseline Hb/ferritin/TSAT, documentation of oral iron trial or valid exception, product-specific FDA indication alignment, monitoring plans for hypersensitivity, and awareness of experimental/investigational exclusions and ICD-10 denial triggers to avoid claim denials.

• Ensure J-code matches product/formulation (eg J1439, J1750, J1756, J2916, J1443, J1444)
• Provide labs (Hb, ferritin, TSAT), prior therapy history, and rationale for IV iron
• Confirm indication is not listed as experimental/investigational and ICD-10 codes are appropriate